title: Update on JAK2 Inhibitors in Myeloproliferative Neoplasm.
abstract: Since the discovery of mutant Janus Kinase 2 (JAK2), JAK2 V617F, in a major proportion of myeloproliferative neoplasm (MPN) patients, there has been a flurry of activity in the development of JAK2 inhibitors. Pan-JAK, predominantly JAK2 and off-target JAK2 inhibitors have been developed in the short span of the past 5 years. These compounds have since been tested to varying success in both in vitro and in vivo settings with several proceeding on to advanced clinical trials. Although it was hoped that these inhibitors would be the silver bullet in the manner than imatinib was to chronic myeloid leukemia, it is becoming apparent that this is not the case for various reasons, chief of which is that a significant reduction of the underlying pathogenic clone is not achieved. In fact, the very notion that the target of JAK2 inhibitors (be it pan-JAK or JAK2 specific) is the mutant JAK2 V617F is being challenged with findings from several clinical trials showing a poor correlation between the reduction in JAK2 V617F mutant allele burden and clinical response. In view of this, it is not surprising that several groups are now investigating combinations of JAK2 inhibitors and other agents in MPN. Although much knowledge has been added in this short span of time, it is apparent that our understanding of the role of JAK2 inhibitors in the treatment scheme of MPN is only beginning.
authors.affiliation: Department of Hematology-Oncology, National University Hospital, Singapore and Hematology/Oncology, Cedars-Sinai Medical Center, Los Angeles CA, USA.
authors.forename: Daniel
authors.initials: D
authors.lastname: Chan
authors.forename: Maya
authors.initials: M
authors.lastname: Koren-Michowitz
keywords: JAK2 V617F; JAK2 inhibitors; myeloproliferative neoplasm
references.citation: Cancer Sci. 2008 Jun;99(6):1265-73
references.pmid: 18482053
references.citation: J Clin Oncol. 2011 Mar 1;29(7):789-96
references.pmid: 21220608
references.citation: Blood. 2006 Nov 15;108(10):3472-6
references.pmid: 16868251
references.citation: Blood. 2007 Mar 1;109(5):2202-4
references.pmid: 17068151
references.citation: Blood. 2007 Jan 1;109(1):71-7
references.pmid: 16954506
references.citation: N Engl J Med. 2007 Feb 1;356(5):459-68
references.pmid: 17267906
references.citation: Leukemia. 2010 Jul;24(7):1302-9
references.pmid: 20508616
references.citation: Mol Cancer Ther. 2008 May;7(5):1176-84
references.pmid: 18483305
references.citation: Cancer. 2007 Nov 1;110(9):2012-8
references.pmid: 17849460
references.citation: Leukemia. 2007 Aug;21(8):1658-68
references.pmid: 17541402
references.citation: N Engl J Med. 2005 Apr 28;352(17):1779-90
references.pmid: 15858187
references.citation: Blood. 2010 Feb 11;115(6):1131-6
references.pmid: 20008298
references.citation: PLoS Med. 2006 Jul;3(7):e270
references.pmid: 16834459
references.citation: Immunol Rev. 2009 Mar;228(1):273-87
references.pmid: 19290934
references.citation: Lancet. 2005 Mar 19-25;365(9464):1054-61
references.pmid: 15781101
references.citation: Nature. 2005 Apr 28;434(7037):1144-8
references.pmid: 15793561
references.citation: Blood. 2006 Aug 15;108(4):1377-80
references.pmid: 16675710
references.citation: Am J Hematol. 2008 Jun;83(6):491-7
references.pmid: 18429051
references.citation: Blood. 2009 Jun 11;113(24):6182-92
references.pmid: 19387008
references.citation: Blood. 2007 Aug 1;110(3):1013-21
references.pmid: 17389763
references.citation: Blood. 2008 Sep 15;112(6):2190-8
references.pmid: 18779404
references.citation: Blood. 2006 Oct 15;108(8):2770-9
references.pmid: 16804112
references.citation: N Engl J Med. 2010 Sep 16;363(12):1117-27
references.pmid: 20843246
references.citation: Blood. 2010 Aug 12;116(6):988-92
references.pmid: 20404132
references.citation: Blood. 2008 Jun 15;111(12):5663-71
references.pmid: 17984313
references.citation: Cancer Cell. 2010 Nov 16;18(5):524-35
references.pmid: 21074499
references.citation: Nature. 2009 Oct 8;461(7265):819-22
references.pmid: 19783980
references.citation: Blood. 2009 Mar 26;113(13):2895-901
references.pmid: 18988864
references.citation: Blood. 2009 Dec 3;114(24):5024-33
references.pmid: 19828702
references.citation: Blood. 2006 Aug 15;108(4):1158-64
references.pmid: 16609064
references.citation: Blood. 2005 Feb 1;105(3):973-7
references.pmid: 15388582
references.citation: Cancer Cell. 2005 Apr;7(4):387-97
references.pmid: 15837627
references.citation: Cancer Cell. 2008 Apr;13(4):311-20
references.pmid: 18394554
references.citation: Blood. 1999 May 1;93(9):2831-8
references.pmid: 10216077
references.citation: Nat Rev Cancer. 2007 Sep;7(9):673-83
references.pmid: 17721432
references.citation: Leuk Res. 2009 Dec;33(12):1581-3
references.pmid: 19573914
references.citation: Br J Cancer. 2010 May 25;102(11):1592-9
references.pmid: 20461084
references.citation: Leuk Res. 2011 May;35(5):608-13
references.pmid: 20727590
references.citation: J Biol Chem. 2007 Jul 13;282(28):20059-63
references.pmid: 17502367
references.citation: Proc Natl Acad Sci U S A. 2006 Apr 18;103(16):6224-9
references.pmid: 16603627
references.citation: Exp Hematol. 2007 Jan;35(1):32-8
references.pmid: 17198871
references.citation: Leukemia. 2010 Jul;24(7):1290-8
references.pmid: 20508609
references.citation: Leuk Res. 2007 Oct;31(10):1389-92
references.pmid: 17328948
references.citation: Blood. 2009 May 14;113(20):4829-33
references.pmid: 19278953
references.citation: Blood. 2006 Sep 1;108(5):1497-503
references.pmid: 16675707
references.citation: Leukemia. 2008 Apr;22(4):740-7
references.pmid: 18079739
references.citation: Leukemia. 2008 Jun;22(6):1289
references.pmid: 18079740
references.citation: Leukemia. 2010 Jun;24(6):1146-51
references.pmid: 20410924
references.citation: J Biol Chem. 2007 Feb 9;282(6):3428-32
references.pmid: 17178722
references.citation: Cancer Res. 2007 Dec 1;67(23):11291-9
references.pmid: 18056455
references.citation: IDrugs. 2008 Oct;11(10):705-9
references.pmid: 18828066
references.citation: Leukemia. 2011 Feb;25(2):301-4
references.pmid: 21052089
references.citation: Br J Haematol. 2010 Aug;150(4):446-55
references.pmid: 20560970
references.citation: Cancer Cell. 2005 Apr;7(4):291-3
references.pmid: 15837617
references.citation: Leuk Lymphoma. 2005 Mar;46(3):447-50
references.pmid: 15621837
references.citation: Leukemia. 2012 Feb;26(2):280-8
references.pmid: 22015772
references.citation: Clin Lymphoma Myeloma. 2009;9 Suppl 3:S340-5
references.pmid: 19778862
references.citation: N Engl J Med. 2009 May 28;360(22):2289-301
references.pmid: 19474426
references.citation: J Clin Oncol. 2009 Nov 10;27(32):5418-24
references.pmid: 19826111
references.citation: Blood. 2006 Sep 15;108(6):2037-40
references.pmid: 16709929
references.citation: Leukemia. 2009 Aug;23(8):1441-5
references.pmid: 19295546
references.citation: Haematologica. 2005 Oct;90(10):1333-8
references.pmid: 16219569
references.citation: Clin Cancer Res. 2008 Feb 1;14(3):788-96
references.pmid: 18245540
references.citation: Genome Biol. 2004;5(12):253
references.pmid: 15575979
references.citation: Med Oncol. 2007;24(1):63-70
references.pmid: 17673813
references.citation: Nat Genet. 2010 Aug;42(8):722-6
references.pmid: 20601953
references.citation: Leukemia. 2009 Nov;23(11):2183-6
references.pmid: 19609284